Stay updated on Nivolumab for Peripheral T-cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the results of a phase II trial studying the effectiveness of nivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:15.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of eligibility criteria such as a person's general health condition or prior treatments.
    Difference
    41%
    Check dated 2024-05-22T21:18:30.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:45:11.000Z thumbnail image

Stay in the know with updates to Nivolumab for Peripheral T-cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.